2020年11月20日 · Purpose: Limitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in the treatment of endometrial cancer include tolerability and cumbersome scheduling. The …

2020年9月29日 · GOG0209 was a phase III, randomized, noninferiority, open-label trial. Inclusion criteria were stage III, stage IV, and recurrent endometrial cancers; performance status 0-2; …

Objective: Compared to 3 cycles, to determine if 6 cycles of adjuvant carboplatin (C) and paclitaxel (P) significantly lower the rate of recurrence in surgically staged patients with stage …

2003年8月25日 · METHODS GOG0209 was a phase III, randomized, noninferiority, open-label trial. Inclusion criteria were stage III, stage IV, and recurrent endometrial cancers; performance …

This objective was addressed by protocol GOG 209, designed to compare the commonly used and popular regimen carboplatin/paclitaxel (CT) to the triplet TAP. The CT regimen had been …

2024年8月28日 · GOG-209, an open-label, randomized, non-inferiority phase III trial, compared carboplatin plus paclitaxel and TAP in patients with chemotherapy-naive unresectable stage...

2012年10月31日 · The GOG 209 study looked to simplify treatment of advanced endometrial cancer, which consists of the three drug regimen of paclitaxel, doxorubicin and cisplatin. This …

2024年2月2日 · GOG 209 Miller DS, et al. J Clin Oncol. 2020 Nov 20;38(33):3841-3850. Key eligibility criteria • Stage III, Stage IV or recurrent endometrial carcinoma. No mandate for …

2019年6月12日 · In this randomized phase 3 trial, we tested whether 6 months of platinum-based chemotherapy plus radiation therapy (chemoradiotherapy) is associated with longer relapse …

A large randomized, noninferiority study (Gynecologic Oncology Group study 209 [GOG 209]) of initial therapy for endometrial cancer showed that PC was not inferior to a three drug …